Emcure Pharmaceuticals Q1 profit surges 36% on international growth

Emcure Pharmaceuticals reported a 36% year-on-year increase in consolidated net profit for the first quarter ended June 30, reaching ₹292.5 crore.

The Mumbai-based drugmaker attributed the gain to robust performance across its international business segments, which continue to serve as the primary growth engine for the company.

Granules India recently reported a nearly 60% profit jump driven by expanding margins in complex generics, while GlaxoSmithKline Pharmaceuticals posted a 16% increase in consolidated net profit for the same period.

The result underscores the resilience of India’s generic pharmaceutical exporters, which are benefiting from sustained demand in key Western markets.

Emcure’s profit growth significantly outpaces the broader industry average, highlighting the company’s ability to capture market share and maintain pricing power in its core therapeutic areas.

This performance aligns with a positive trend among Indian pharma peers.

Granules India recently reported a nearly 60% profit jump driven by expanding margins in complex generics, while GlaxoSmithKline Pharmaceuticals posted a 16% increase in consolidated net profit for the same period.